CN107278152A - 醋酸阿比特龙复合物、其制备方法及包含它们的药物组合物 - Google Patents

醋酸阿比特龙复合物、其制备方法及包含它们的药物组合物 Download PDF

Info

Publication number
CN107278152A
CN107278152A CN201680009531.4A CN201680009531A CN107278152A CN 107278152 A CN107278152 A CN 107278152A CN 201680009531 A CN201680009531 A CN 201680009531A CN 107278152 A CN107278152 A CN 107278152A
Authority
CN
China
Prior art keywords
abiraterone acetate
complex
acetate
abiraterone
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680009531.4A
Other languages
English (en)
Chinese (zh)
Inventor
R·安吉
T·乔丹
O·巴萨-德尼斯
T·索里莫斯
Z·奥特沃斯
H·格拉维纳斯
G·菲利普西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tavanta Therapeutics Hungary Inc
Original Assignee
Druggability Technologies IP Holdco Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Druggability Technologies IP Holdco Ltd filed Critical Druggability Technologies IP Holdco Ltd
Publication of CN107278152A publication Critical patent/CN107278152A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680009531.4A 2015-02-09 2016-02-09 醋酸阿比特龙复合物、其制备方法及包含它们的药物组合物 Pending CN107278152A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP1500055 2015-02-09
HU1500055A HUP1500055A1 (hu) 2015-02-09 2015-02-09 Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények
PCT/IB2016/050672 WO2016128891A1 (en) 2015-02-09 2016-02-09 Complexes of abiraterone acetate, process for the preparation thereof and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
CN107278152A true CN107278152A (zh) 2017-10-20

Family

ID=89991732

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680009531.4A Pending CN107278152A (zh) 2015-02-09 2016-02-09 醋酸阿比特龙复合物、其制备方法及包含它们的药物组合物

Country Status (18)

Country Link
US (4) US9623034B2 (enExample)
EP (1) EP3256108B1 (enExample)
JP (1) JP6697473B2 (enExample)
CN (1) CN107278152A (enExample)
AR (1) AR103653A1 (enExample)
AU (1) AU2016217534A1 (enExample)
BR (1) BR112017017089A2 (enExample)
CA (1) CA2976053A1 (enExample)
ES (1) ES2737955T3 (enExample)
HK (1) HK1246189B (enExample)
HU (2) HUP1500055A1 (enExample)
IL (1) IL253793B (enExample)
MX (1) MX2017010280A (enExample)
PL (1) PL3256108T3 (enExample)
RU (1) RU2017129740A (enExample)
SG (1) SG11201706273QA (enExample)
TW (1) TWI696463B (enExample)
WO (1) WO2016128891A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110170058A (zh) * 2019-06-24 2019-08-27 李建恒 一种阿比特龙包合物及其制备方法
CN111617258A (zh) * 2019-02-28 2020-09-04 江苏恒瑞医药股份有限公司 一种制备阿比特龙或其衍生物药物组合物的方法及其应用
WO2021057042A1 (zh) 2019-09-26 2021-04-01 湖南慧泽生物医药科技有限公司 一种含有醋酸阿比特龙的药物组合物及其制备方法和应用
CN115427016A (zh) * 2020-04-16 2022-12-02 塔凡塔医疗匈牙利公司 用于治疗前列腺癌的方法和组合物
EP4197541A1 (en) 2021-12-15 2023-06-21 Hunan Huize Biopharma S&T Co., Ltd Abiraterone acetate-containing composition and application thereof

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP1500055A1 (hu) 2015-02-09 2016-08-29 Druggability Technologies Ip Holdco Ltd Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
US10080762B2 (en) 2016-12-14 2018-09-25 Druggability Technologies Ip Holdco Limited Pharmaceutical composition containing Celecoxib
EP3554508A4 (en) * 2016-12-19 2020-08-05 Druggability Technologies IP Holdco Limited SUVOREXANT PHARMACEUTICAL FORMULATIONS
AU2018316248A1 (en) * 2017-08-09 2020-01-30 Nangenex Nanotechnology Incorporated Pharmaceutical composition comprising Abiraterone acetate and Darulotamide
CZ2019168A3 (cs) 2019-03-20 2020-09-30 Zentiva, K.S. Farmaceutická kompozice obsahující abirateron acetát
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
CN120091828A (zh) * 2022-10-12 2025-06-03 中外制药株式会社 含有肽、表面活性剂和聚合物的组合物
WO2025059166A1 (en) * 2023-09-11 2025-03-20 Particle Solutions Llc Compositions and methods for treating skin inflammation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012140220A1 (en) * 2011-04-15 2012-10-18 Janssen Pharmaceutica Nv Freeze dried drug nanosuspensions
WO2014009437A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
EP2813212A1 (en) * 2013-06-10 2014-12-17 Zentiva, a.s. Drug formulation using API in nanofibers

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
WO1995011914A1 (en) 1993-10-27 1995-05-04 Merrell Pharmaceuticals Inc. Δ16 unsaturated c¿17? heterocyclic steroids useful as steroid c17-20 lyase inhibitors
US5688977A (en) 1996-02-29 1997-11-18 Napro Biotherapeutics, Inc. Method for docetaxel synthesis
JP4923182B2 (ja) 2003-02-28 2012-04-25 マクニール−ピーピーシー・インコーポレーテツド セレコキシブ及びニコチンアミド共結晶並びにこの共結晶を含む医薬組成物
WO2007150030A2 (en) * 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20090124587A1 (en) 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
US9278134B2 (en) 2008-12-29 2016-03-08 The Board Of Trustees Of The University Of Alabama Dual functioning ionic liquids and salts thereof
CN101768199B (zh) 2009-12-24 2014-03-26 深圳万乐药业有限公司 醋酸阿比特龙的多晶型物及其制备方法
HUP1000325A2 (en) * 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Nanostructured aprepitant compositions and process for their preparation
CN102558275A (zh) 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
CN102321142A (zh) 2011-09-29 2012-01-18 重庆医药工业研究院有限责任公司 一种醋酸阿比特龙晶型及其制备方法
CN102336801B (zh) 2011-10-31 2013-05-15 南京卡文迪许生物工程技术有限公司 醋酸阿比特龙多晶型物和药用组合物
US9662807B2 (en) * 2011-12-21 2017-05-30 GKN Aerospace Services Structures, Corp. Method for forming a fabric preform for a composite material by separately tensioning tows
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009434A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014083512A1 (en) 2012-11-28 2014-06-05 Dr. Reddy's Laboratories Limited Process for preparation of abiraterone acetate
US10195150B2 (en) 2012-12-20 2019-02-05 Kashiv Pharma, Llc Orally disintegrating tablet formulation for enhanced bioavailability
EP2938625B1 (en) 2012-12-31 2018-02-21 Hetero Research Foundation Process for the preparation of abiraterone acetate
KR20160023641A (ko) 2013-03-15 2016-03-03 아이슈티카 인코포레이티드 아비라테론 아세테이트 제제
HUP1500055A1 (hu) 2015-02-09 2016-08-29 Druggability Technologies Ip Holdco Ltd Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012140220A1 (en) * 2011-04-15 2012-10-18 Janssen Pharmaceutica Nv Freeze dried drug nanosuspensions
WO2014009437A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
EP2813212A1 (en) * 2013-06-10 2014-12-17 Zentiva, a.s. Drug formulation using API in nanofibers

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111617258A (zh) * 2019-02-28 2020-09-04 江苏恒瑞医药股份有限公司 一种制备阿比特龙或其衍生物药物组合物的方法及其应用
CN110170058A (zh) * 2019-06-24 2019-08-27 李建恒 一种阿比特龙包合物及其制备方法
CN110170058B (zh) * 2019-06-24 2022-02-11 李建恒 一种阿比特龙包合物及其制备方法
WO2021057042A1 (zh) 2019-09-26 2021-04-01 湖南慧泽生物医药科技有限公司 一种含有醋酸阿比特龙的药物组合物及其制备方法和应用
CN115427016A (zh) * 2020-04-16 2022-12-02 塔凡塔医疗匈牙利公司 用于治疗前列腺癌的方法和组合物
EP4197541A1 (en) 2021-12-15 2023-06-21 Hunan Huize Biopharma S&T Co., Ltd Abiraterone acetate-containing composition and application thereof
US11806313B2 (en) 2021-12-15 2023-11-07 Hunan Huize Biopharma S&T Co., Ltd. Abiraterone acetate containing composition and application thereof

Also Published As

Publication number Publication date
US9592244B2 (en) 2017-03-14
EP3256108A1 (en) 2017-12-20
BR112017017089A2 (pt) 2018-06-26
US9623034B2 (en) 2017-04-18
JP2018504443A (ja) 2018-02-15
US10130582B2 (en) 2018-11-20
US10668016B2 (en) 2020-06-02
EP3256108B1 (en) 2019-05-01
RU2017129740A (ru) 2019-03-11
HK1246189B (en) 2020-03-27
ES2737955T3 (es) 2020-01-17
IL253793A0 (en) 2017-09-28
RU2017129740A3 (enExample) 2019-08-06
PL3256108T3 (pl) 2019-12-31
TW201639580A (zh) 2016-11-16
JP6697473B2 (ja) 2020-05-20
AU2016217534A1 (en) 2017-09-07
IL253793B (en) 2021-02-28
SG11201706273QA (en) 2017-08-30
HUE045398T2 (hu) 2019-12-30
US20190046437A1 (en) 2019-02-14
MX2017010280A (es) 2017-12-04
WO2016128891A1 (en) 2016-08-18
HUP1500055A1 (hu) 2016-08-29
TWI696463B (zh) 2020-06-21
US20160228455A1 (en) 2016-08-11
AR103653A1 (es) 2017-05-24
US20160331763A1 (en) 2016-11-17
US20170182172A1 (en) 2017-06-29
CA2976053A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
US10668016B2 (en) Complexes of abiraterone acetate, process for the preparation thereof and pharmaceutical compositions containing them
HK1246189A1 (en) Complexes of abiraterone acetate, process for the preparation thereof and pharmaceutical compositions containing them
KR102121404B1 (ko) 아비라테론 아세테이트 제제
WO2014009436A1 (en) Nanosuspension of abiraterone acetate
CN106265580B (zh) Somcl-9112固体分散体、其制备方法及包含其的somcl-9112固体制剂
EP4079295A1 (en) Composition having improved solubility and bioavailability of olaparib
WO2015032873A1 (en) High-load pharmaceutical compositions comprising abiraterone acetate
TW201540303A (zh) 法洛德及其衍生物的錯合物、製備製程以及藥品組合物
CN108495620A (zh) 包含苯基氨基嘧啶衍生物的药物组合物
US20200197416A1 (en) Pharmaceutical composition comprising abiraterone acetate and darulotamide
CN111278432A (zh) 来那度胺速释制剂
US20080226734A1 (en) Combination of a narcotic and non-narcotic analgesic
CN107427462A (zh) 固态分散体
EP3041462A1 (en) High-load pharmaceutical compositions comprising abiraterone acetate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20171020